Two Directors at Trelleborg AB bought 850 shares at 34.700EUR. The significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...
Trelleborg’s more optimistic outlook comment for Q3 was quite expected, but the growth of the Medical business stood out to us. Nevertheless, we have left our adj. EBITA estimates for 2024–2026 essentially unchanged, and reiterate our SEK430 target price and HOLD. We have historically posited for expanding multiples for Trelleborg, while we now see this gap as being nearly filled.
We estimate Q2 sales of SEK8,677m, organic growth of c0% YOY, and adj. EBITA of SEK1,620m (3% above consensus). We expect a somewhat raised outlook from management as we enter H2, and we have increased our 2024–2026e adj. EBIT by c1% on average. We reiterate our HOLD, but have raised our target price to SEK430 (395) on updated valuation and estimates.
A director at Dana Inc sold 4,357 shares at 14.010USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing...
Overall, Trelleborg’s Q1 was in line with our estimates and consensus, while we believe the outlook comment heading into Q2 might be on the overly cautious side. We have made limited (1% on average) estimate changes on adj. EBITA for 2024–2026e and reiterate our HOLD. We have raised our target price to SEK395 (380) and see limited upside potential for the stock.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.